

Table S2. Monoclonal antibodies used in chromatogram binding assays.

| <u>Antibody</u> | <u>Clone/Designation</u> | <u>Manufacturer/Reference</u> | <u>Dilution</u> | <u>Isotype</u> | <u>hESC binding¹</u> |
|-------------------------------------|--------------------------|-------------------------------|-----------------|----------------|---------------------------------|
| Anti-SSEA-4 | MC-813-70 | eBioScience | 1:100 | IgG3 | + |
| Anti-sialyl-Lewis ^x | KM93 | Merck | 1:50 | IgM | - |
| Anti-sialyl-Lewis ^a | 116-NS-19-9 | Signet | 1:30 | IgG1 | - |
| Anti-GD1a | GD1a-1 | Millipore | 1:100 | IgG1 | - |
| Anti-HNK-1 | VC1.1 | Sigma | 1:50 | IgM | - |
| Anti-SO ₃ -3Gal β | Sulph-1 | (1) ² | 1:100 | IgG1 | + |
| Anti-GM1 | GM1:1 | (2) | 1:50 | IgM | - |
| Anti-GM2 | DMAb-1 | (3) | 1:50 | IgM | - |
| Anti-GD3 | DMAb-7 | (4) | 1:100 | IgM | - |
| Anti-sialyl-lactotetra | TR4/SL-50 | (5) | 1:1000 | IgM | + |
| Anti-di-sialyl-lactotetra | DMAb22 | (6) | 1:2000 | IgM | - |
| Anti-NeuAc α 3-neolactotetra | LM1:1a | (7) | 1:1000 | IgM | - |
| Anti-NeuAc α 6-neolactotetra | LM4:2 | (8) | 1:100 | IgG | - |

¹Binding is defined as follows: + denotes a binding when 40 μ g of the acid glycosphingolipid fraction of hESC SA181 or SA121 was applied on the thin-layer chromatogram, while - denotes no binding.

²References:

1. Fredman, P., Mattson, L., Andersson, K., Davidsson, P., Ishizuka, I., Jeansson, S., Månsson, J.-E., and Svennerholm, L. (1988) Characterization of the binding epitope of a monoclonal antibody to sulphatide. *Biochem. J.* **251**, 17-22
2. Molander, M., Berthold, C.H., Persson, H., Andersson, K., and Fredman, P. (1997) Monosialoganglioside (GM1) immunofluorescence in rat spinal roots studied with a monoclonal antibody. *J. Neurocytol.* **26**, 101-111
3. Karlsson, G., Månsson, J.E., Wikstrand, C., Bigner, D., and Svennerholm, L. (1990) Characterization of the binding epitope of the monoclonal antibody DMAb-1 to ganglioside GM2. *Biochim. Biophys. Acta* **1043**, 267-272
4. He, X., Wikstrand, C.J., Fredman, P., Månsson, J.E., Svennerholm, L., and Bigner, D.D. (1989) GD3 expression by cultured human tumor cells of neuroectodermal origin. *Acta. Neuropathol.* **79**, 317-325
5. Wikstrand, C.J., Longee, D.C., McLendon, R.E., Fuller, G.N., Friedman, H.S., Fredman, P., Svennerholm, L., and Bigner, D.D. (1993) Lactotetraose series ganglioside 3'6'-isoLD1 in tumors of central nervous and other systems *in vitro* and *in vivo*. *Cancer Res.* **53**, 120-126
6. Svennerholm, L., Boström, K., Fredman, P., Månsson, J.-E., Rosengren, B., and Rynmark, B.-M. (1989) Human brain gangliosides: developmental changes from early fetal stage to advanced age. *Biochim. Biophys. Acta* **1005**, 109-117
7. Svennerholm, L., Rynmark, B.M., Vilbersson, G., Fredman, P., Gottfries, J., Månsson, J.-E., and Percy, A. (1991) Gangliosides in human fetal brain. *J. Neurochem.* **56**, 1763-1768
8. Nilsson, O., Lindholm, L., Holmgren, J. and Svennerholm, L. (1985) Monoclonal antibodies raised against NeuAc α 2-6neolactotetraosylceramide detect carcinoma-associated gangliosides. *Biochim. Biophys. Acta* **835**, 577-583